Caveolin-1 mediates chemoresistance in breast cancer stem cells via β-catenin/ABCG2 signaling pathway

Carcinogenesis

Volumn 35, Issue 10, 2014, Pages 2346-2356

  Wang, Zhiyu ^a,b   Wang, Neng ^b   Li, Wenping ^c   Liu, Pengxi ^a   Chen, Qianjun ^a   Situ, Honglin ^a   Zhong, Shaowen ^a   Guo, Li ^a   Lin, Yi ^a   Shen, Jiangang ^b   Chen, Jianping ^b  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

^c Guangdong Women and Child Health Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BREAST CANCER RESISTANCE PROTEIN; CAVEOLIN 1; CYCLIN D1; EPIRUBICIN; FLUOROURACIL; GLYCOGEN SYNTHASE KINASE 3BETA; MYC PROTEIN; PACLITAXEL; PROTEIN KINASE B; SURVIVIN; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CAV1 PROTEIN, HUMAN; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STEM CELL SELF-RENEWAL; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; ANIMAL; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BETA CATENIN; BREAST NEOPLASMS; CAVEOLIN 1; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908599867     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu155     Document Type: Article

References (50)

1. DeSantis, C. et al. (2014) Breast cancer statistics. CA. Cancer J. Clin., 64, 52-62.
2. Kuczynski, E.A. et al. (2013) Drug rechallenge and treatment beyond progression-implications for drug resistance. Nat. Rev. Clin. Oncol., 10, 571-587.
3. Szakács, G. et al. (2006) Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov., 5, 219-234.
4. Malik, B. et al. (2012) Cancer stem cells and resistance to chemo and radio therapy. Front. Biosci. (Elite Ed)., 4, 2142-2149.
5. Maugeri-Saccà, M. et al. (2011) Cancer stem cells and chemosensitivity. Clin. Cancer Res., 17, 4942-4947.
6. Holohan, C. et al. (2013) Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer, 13, 714-726.
7. Pérez-Tomás, R. (2006) Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem., 13, 1859-1876.
8. Wu, C.P. et al. (2011) Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy. Curr. Pharm. Biotechnol., 12, 609-620.
9. Elliott, A. et al. (2010) The ABCs of cancer stem cell drug resistance. IDrugs, 13, 632-635.
10. Dean, M. (2009) ABC transporters, drug resistance, and cancer stem cells. J. Mammary Gland Biol. Neoplasia, 14, 3-9.
11. Tanei, T. et al. (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res., 15, 4234-4241.
12. Neumeister, V. et al. (2010) In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am. J. Pathol., 176, 2131-2138.
13. Heidel, F.H. et al. (2012) Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell, 10, 412-424.
14. Cui, J. et al. (2012) Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer. Curr. Pharm. Des., 18, 2464-2471.
15. Yeung, J. et al. (2010) β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell, 18, 606-618.
16. Patani, N. et al. (2012) The role of caveolin-1 in human breast cancer. Breast Cancer Res. Treat., 131, 1-15.
17. Ho, C.C. et al. (2008) Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer, 59, 105-110.
18. Selga, E. et al. (2008) Role of caveolin 1, E-cadherin, Enolase 2 and PKCalpha on resistance to methotrexate in human HT29 colon cancer cells. BMC Med. Genomics, 1, 35.
19. Cai, C. et al. (2004) Overexpression of caveolin-1 induces alteration of multidrug resistance in Hs578T breast adenocarcinoma cells. Int. J. Cancer, 111, 522-529.
20. Sekhar, S.C. et al. (2013) Identification of caveolin-1 as a potential causative factor in the generation of trastuzumab resistance in breast cancer cells. J. Cancer, 4, 391-401.
21. Pang, A. et al. (2004) Caveolin-1 gene is coordinately regulated with the multidrug resistance 1 gene in normal and leukemic bone marrow. Leuk. Res., 28, 973-977.
22. Park, J.H. et al. (2011) Involvement of caveolin-1 in fibronectin-induced mouse embryonic stem cell proliferation: role of FAK, RhoA, PI3K/Akt, and ERK = pathways. J. Cell. Physiol., 226, 267-275.
23. Bonuccelli, G. et al. (2009) Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature. Am. J. Pathol., 174, 1650-1662.
24. Prosperi, J.R. et al. (2010) A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer. Curr. Drug Targets, 11, 1074-1088.
25. Michaelson, J.S. et al. (2001) beta-catenin is a downstream effector of Wntmediated tumorigenesis in the mammary gland. Oncogene, 20, 5093-5099.
26. Yao, H. et al. (2011) Targeting the Wnt/β-catenin signaling pathway in human cancers. Expert Opin. Ther. Targets, 15, 873-887.
27. Fodde, R. et al. (2007) Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr. Opin. Cell Biol., 19, 150-158.
28. Mitsiades, C.S. et al. (2004) The Akt pathway: molecular targets for anticancer drug development. Curr. Cancer Drug Targets, 4, 235-256.
29. Li, H. et al. (2013) Stem cell marker aldehyde dehydrogenase 1 (ALDH1)-expressing cells are enriched in triple-negative breast cancer. Int. J. Biol. Markers, 28, e357-e364.
30. Yin, S. et al. (2013) Tumor-initiating cells and FZD8 play a major role in drug resistance in triple-negative breast cancer. Mol. Cancer Ther., 12, 491-498.
31. Kuo, W.H. et al. (2012) Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas. PLoS One, 7, e45831.
32. Saphner, T. et al. (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol., 14, 2738-2746.
33. Almendro, V. et al. (2014) Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep., 6, 514-527.
34. Nguyen, L.V. et al. (2012) Cancer stem cells: an evolving concept. Nat. Rev. Cancer, 12, 133-143.
35. Kvinlaug, B.T. et al. (2007) Targeting cancer stem cells. Expert Opin. Ther. Targets, 11, 915-927.
36. Boman, B.M. et al. (2008) Cancer stem cells: a step toward the cure. J. Clin. Oncol., 26, 2795-2799.
37. Dean, M. et al. (2005) Tumour stem cells and drug resistance. Nat. Rev. Cancer, 5, 275-284.
38. Fiucci, G. et al. (2002) Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene, 21, 2365-2375.
39. Engelman, J.A. et al. (1997) Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J. Biol. Chem., 272, 16374-16381.
40. Engelman, J.A. et al. (1998) Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J. Biol. Chem., 273, 20448-20455.
41. Sagara, Y. et al. (2004) Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer. Br. J. Cancer, 91, 959-965.
42. Park, S.S. et al. (2005) Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast. Histopathology, 47, 625-630.
43. Sell, S. (2006) Cancer stem cells and differentiation therapy. Tumour Biol., 27, 59-70.
44. Wu, X.Z. (2008) Origin of cancer stem cells: the role of self-renewal and differentiation. Ann. Surg. Oncol., 15, 407-414.
45. Chau, W.K. et al. (2013) c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling. Oncogene, 32, 2767-2781.
46. Khramtsov, A.I. et al. (2010) Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am. J. Pathol., 176, 2911-2920.
47. López-Knowles, E. et al. (2010) Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol. Biomarkers Prev., 19, 301-309.
48. Alshenawy, H.A. et al. (2013) Differential caveolin-1 expression in colon carcinoma and its relation to E-cadherin-β-catenin complex. Ann. Diagn. Pathol., 17, 476-482.
49. Gortazar, A.R. et al. (2013) Crosstalk between caveolin-1/extracellular signal-regulated kinase (ERK) and β-catenin survival pathways in osteocyte mechanotransduction. J. Biol. Chem., 288, 8168-8175.
50. Elsheikh, S.E. et al. (2008) Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br. J. Cancer, 99, 327-334.